Condition: Cushing Syndrome · Metabolic Syndrome · Sponsor: Central Hospital, Nancy, France
The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome. the HEPACORT study is the first exploratory study to assess the severity of liver fibrosis in patients with Cushing's syndrome or suspected of presenting by Magnetic Resonance Elastography (MRE).
This description comes directly from the study's public registry record.
Nicolas SCHEYER, MD · +33383154302 · n.scheyer@chru-nancy.fr
Guillaume DROUOT, PhD · +33383157666 · g.drouot@chru-nancy.fr
Always discuss trial participation with your own doctor first.
| CHRU Nancy | Nancy, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05911620